CRH Medical Corp. | StockChase
81
CRH Medical Corp. (CRH-T)

Last Price Recorded: $2.5200 on 2017-11-24

ON STOCKCHASE SINCE Jul 2009

biotechnology/pharmaceutical

CRH Medical Corp.


Signal Opinion Expert
     

2009-07-14

BUY
CRH Medical Corp. (CRH-T)
Small medical products company with primarily US operations and involved in haemorrhoid banding. Have their own clinics where they treat patients and also sell their product direct to physicians. Excellent company. Very early in rolling out their product so there is bound to be volatility. Good treat it as a trading stock.
biotechnology/pharmaceutical
Karl Berger

Partner, Toron Investment Management

Price: $1.630
Owned: No

2014-12-24

TOP PICK
CRH Medical Corp. (CRH-T)

A little company based in Vancouver that just had a transformational US acquisition. They are in the hemorrhoid business with clinics where people go in for procedures. This is one of those companies that is off the radar screen. His sense is that this is a $2.50 stock in a year’s time.

biotechnology/pharmaceutical
Jason Donville

President & CEO, Donville Kent Asset Management

Price: $1.700
Owned: Yes

2015-01-14

COMMENT
CRH Medical Corp. (CRH-T)

CRH Medical (CRH-T) or Merus Labs (MSL-T)? These are not really comparable to one another. This is the one that looks very interesting. Just made an acquisition at the beginning of December, and the stock had a big run. It looks like they could produce some really high numbers. If he were buying one or the other, it would probably be this one.

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investment Management Inc.

Price: $2.040
Owned: No

2015-02-05

HOLD
CRH Medical Corp. (CRH-T)

This is getting ahead of itself. Likes the company and thinks the management team is great, but he needs to see more details before he could add more capital. He knows there are more acquisitions coming in after that, but put the current one to bed. If you are going to grow through acquisitions you have to show that you can acquire intelligently and integrate the acquisitions. Considers this as a “strong hold”.

biotechnology/pharmaceutical
Jason Donville

President & CEO, Donville Kent Asset Management

Price: $2.510
Owned: Yes

2015-02-23

BUY
CRH Medical Corp. (CRH-T)

Hemorrhoid business.  Acquisition they made is quite accretive.  People are just becoming aware of this story.  A high margin business.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $3.800
Owned: Unknown

2015-04-08

COMMENT
CRH Medical Corp. (CRH-T)

A very interesting business. Their initial business was a solution for hemorrhoids. They made a transformational acquisition a few months ago of anaesthesiology services, specifically in the gastrointestinal area. They are seeing growth from an acquisition standpoint, but also from an organic standpoint now.

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investment Management Inc.

Price: $3.500
Owned: Yes

2015-05-01

BUY on WEAKNESS
CRH Medical Corp. (CRH-T)

(Market Call Minute.) A growth by acquisition story. Has doubled in the last 6 months.

biotechnology/pharmaceutical
Bruce Campbell (1)

President, Campbell and Lee InvMngmnt

Price: $3.480
Owned: No

2015-05-06

TOP PICK
CRH Medical Corp. (CRH-T)

Had a big acquisition and we have now seen a quarter, which only represents 20% of their year. The quarter was clean. Good management team. Valuation is still reasonable. In a years time this can be a $5 or better stock.

biotechnology/pharmaceutical
Jason Donville

President & CEO, Donville Kent Asset Management

Price: $3.330
Owned: Yes

2015-06-19

TOP PICK
CRH Medical Corp. (CRH-T)

In terms of management, they are a little more conservative than some of the others. They were in the haemorrhoid business, but do a lot of anaesthesia for colonoscopies, etc, and that business has been growing very rapidly. Made a transformative acquisition at the end of last year, and are on the cusp of probably making a couple more over the next 6 months or so. Recent quarter was very strong and expects Q2 to be strong as well.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $4.110
Owned: Yes

2015-06-30

TOP PICK
CRH Medical Corp. (CRH-T)

This is the medical stock that he is the most comfortable with as being a long-term compounder. They do colonoscopy clinics for early detection of cancer. Based in Vancouver. Good management team. Only trading at about 10 or 11 times 2016 earnings. 35% ROE.

biotechnology/pharmaceutical
Jason Donville

President & CEO, Donville Kent Asset Management

Price: $4.740
Owned: Yes

2015-06-30

COMMENT
CRH Medical Corp. (CRH-T)

This is widely liked. He likes the smaller healthcare companies and owns quite a few.

biotechnology/pharmaceutical
Michael Smedley

Exec VP & Chief Investment Officer, Morgan Meighan & Associates

Price: $4.740
Owned: No

2015-08-19

BUY on WEAKNESS
CRH Medical Corp. (CRH-T)

Continue to execute along the lines they said they were going to do. Had a very steady growing small business going back to December, and then they made an acquisition of anaesthesiology clinics and the stock really shot up. Just made another announcement today. Valuation tends to get stretched at times, but when it comes back  it is one you can buy because they are probably going to continue to do acquisitions.

biotechnology/pharmaceutical
Bruce Campbell (2)

President & Portfolio Manager, Stone Castle Investment Management Inc.

Price: $4.560
Owned: Unknown

2015-08-25

TOP PICK
CRH Medical Corp. (CRH-T)

The best small-cap company in Canada that he can recommend. Great management team. 9X 2016 earnings. 31% ROE. He is very comfortable in saying that in 5 years it will be a $25 stock.

biotechnology/pharmaceutical
Jason Donville

President & CEO, Donville Kent Asset Management

Price: $3.930
Owned: Yes

2015-09-08

COMMENT
CRH Medical Corp. (CRH-T)

Distributes medical products to clinics, and buys up other players that do the same type of thing. The challenge with these rollup’s is that they tend to do it with debt, and at very high valuations. This is trading at 25X EBITDA. They don’t really cash flow and this is trading at 45X cash flow. All of their growth is in the future in terms of cash flow growth. You are really counting on their growth to continue. On any kind of miss on earnings or check-back in the space, these stocks don’t have a floor for a fair bit of time before value buyers step in. Not a long-term investment, but something you might want to trade.

biotechnology/pharmaceutical
Jason Mann

CIO & Co-Founder, Edgehill Patners

Price: $5.120
Owned: No

2015-09-28

TOP PICK
CRH Medical Corp. (CRH-T)

Healthcare space.  The management team’s last company sold at a great multiple.  They can get synergies and revenues up.  It sold off here.  It will be a long term hold for him.

biotechnology/pharmaceutical
Peter Imhof

Vice President & Portfolio Manager, AGF Investments Inc

Price: $4.210
Owned: Yes

Showing 1 to 15 of 81 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.